Overview

Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

Status:
Terminated
Trial end date:
2014-10-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in subjects with Huntington's disease (HD).
Phase:
Phase 2
Details
Lead Sponsor:
Omeros Corporation